GlassScriptPhysician profile
Mark T Schreiber
NPI 1124090022
$29,143.17
in general payments reported to CMS, 2019-2025
36 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,862 · 2020: $9,903 · 2021: $3,575 · 2022: $2,028 · 2023: $2,289 · 2024: $1,739 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,664 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,663.76 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,393.00 | 2019-2020 | |
| Abbvie INC. | $4,290.12 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $1,501.78 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,312.08 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,156.44 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $881.49 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $807.25 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $670.77 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $379.00 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $370.39 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $305.93 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $282.99 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $212.82 | 2019-2025 | Trintellix |
| Tris Pharma INC | $210.84 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Avanir Pharmaceuticals, INC. | $169.86 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schreiber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.